Syngenta invests in Avidex
Avidex announced that Syngenta AG has made an investment of £5 million in Avidex in exchange for a minority equity stake. Avidex announced that Dr Ian Kimber of Syngenta will join the Board of Directors of Avidex effective January 1, 2006.
Dr Ian Kimber is a Syngenta Principal Fellow with special interests in, and responsibilities for, immunology, allergy and inflammation. He is based at the Syngenta Central Toxicology Laboratory in Cheshire UK and has served Syngenta, and its legacy companies, for more than 20 years in a variety of scientific and management positions.
His current research interests include all aspects of allergic sensitisation and allergic disease, the biology of dendritic cells and the regulation of cutaneous immune function. Dr Kimber has published over 450 research papers, review articles and book chapters and sits on the editorial boards of immunology, pathology, dermatology and toxicology journals. In addition he serves on a variety of national and international scientific advisory boards and expert committees.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
One-step test for hepatitis C virus infection developed
Brain cancer experts crowdsource a cure for deadly glioblastoma
Amgen to Acquire Abgenix - Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty

CORDOUAN TECHNOLOGIES SAS - Pessac, France

Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. - Düsseldorf, Germany
